L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Levels
Completed · Phase 2 · Has a placebo group
Conditions studied: Asthma, Inflammation
In brief
The major impact of this study will be to identify the adult severe asthma cohort that will benefit from supplemental L-arginine therapy. The investigators hypothesize that a subset of adult severe asthma patients will respond to supplemental L-arginine and derive clinical benefit from the addition of this therapy to standard-of-care asthma medications. The investigators hypothesize that the patients that benefit most will have low exhaled nitric oxide concentrations (\< 20 ppb) at baseline.
Key facts
- Study ID
- NCT01841281
- Run by
- Nicholas Kenyon
- People needed
- 54
- Starts
- 2013-08-01
- Expected to finish
- 2019-12-01
- Last updated by the study team
- 2020-04-21
Who can join
Age: 19 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adults >18 yrs of age
- Diagnosis of severe asthma based on American Thoracic Society Workshop definition (Am J Respir Crit Care Med 2000; 162:2341)
- Active asthma medications of high dose inhaled corticosteroids plus long-acting beta agonist
- History of recent asthma exacerbations or Asthma control test score < 20/25
You may not qualify if…
- <19 yrs of age
- Forced expiratory volume 1sec <30% predicted
- Pregnant or nursing women
- Current smokers or smoking history > 15 pack years
- Actively taking or known intolerance to L-arginine
Where it is running
- UC Davis CTSC Clinical Research Center — Sacramento, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.